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| INTRODUC TI ON
Rheumatoid arthritis (RA), one of the common chronic inflammation diseases, affects approximately 0.5% to 1% of adult population worldwide. RA is characterized by joint damage, substantial disability, and other extra-articular comorbidities, which imposes a huge burden on individuals and society. 1, 2 In order to alleviate disease, several effective treatments have been used, including glucocorticoid, conventional disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitor, and other biologics. 3 Among these, TNF inhibitor could rapidly relieve inflammation and inhibit the progress of radiology to some extent, which are popularly applied in RA patients. However, an estimated 20% to 30% RA patients lack efficacy to TNF inhibitor treatment, or do not tolerate its high cost. 4 Therefore, exploring novel biomarkers for predicting the clinical response to TNF inhibitor in RA patients is necessary. microRNAs (miRNAs), a family of highly conserved small non-coding RNAs directly binding to the 3′-untranslated regions (3′-UTRs), could mediate target genes, protein expression, and signaling pathways to affect cell functions such as proliferation, apoptosis, differentiation, migration, and invasion, thereby contributing to multiple biological processes, such as inflammation formation and immune response. [5] [6] [7] [8] Accumulating evidences have proven that several miRNAs have established their value on the progress of various immune diseases, including RA, systemic lupus erythematosus (SLE), and psoriasis, which uncovered the potential of miRNA as marker for RA progression and prognosis. [9] [10] [11] [12] [13] [14] [15] However, no studies investigate the effect of comprehensive miRNA expression profile on predicting clinical response to TNF inhibitor in RA patients. Thus, in the present study, the aim was to explore the correlation of circulating miRNA expression profile with clinical response to TNF inhibitor in treating active RA patients. 
| ME THODS

| Patients
| Data collection
Baseline features of RA patients were recorded, including age, gender, disease duration, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) status, anti-citrullinated protein antibody (ACPA) status, and biologics history. Besides, DAS28 was evaluated and recorded at baseline as well.
| Sample collection
Baseline peripheral blood sample was obtained from each patient before initiation of TNF inhibitor treatment, and peripheral blood mononuclear cell (PBMC) was subsequently extracted and stored in liquid nitrogen for followed detections.
| Treatment
All patients initiated TNF inhibitor (ETN) treatment for 24 weeks. In brief, patients were given subcutaneous injection of 50 mg ETN per week for 24 weeks. Besides, the concomitant medications of conventional DMARDs were recorded during the study.
| Evaluation of clinical response
DAS28 score was assessed at baseline (W0), 6 weeks (W4), 12 weeks (W12), and 24 weeks (W24). Then, clinical response at W24 was evaluated according to the European League Against Rheumatism (EULAR) response criteria, which was defined as a decrease of 1.2 points in DAS28 score from baseline. 16 Referring to achievement of clinical response at W24, patients were divided into responders and non-responders.
| Microarray assay
Sixteen patients including eight responders and 8 non-responders were selected from total patients. Total RNA was extracted from PBMCs of each patient by TRIzol reagent (Invitrogen), and RNA concentration, purity, and integrity were evaluated and adjusted; then, RNA was subjected to microRNA microarray assay. In brief, the assay started from Finally, a GeneChip Scanner 7G (Affymetrix, USA) was performed to scan that RNA molecule. Owing to the intrinsic background of different chips that might affect the calculation of the expression values, the Robust Multichip Average (RMA) was used for the normalization of the raw data in each chip. As an algorithm applying to create an expression matrix from Affymetrix data, the raw intensity values were background-corrected, log2-transformed, and then quantile-normalized.
After that, data were normalized by a linear model, thereby obtaining an expression measure for each probe set on each array. 17 
| Bioinformatic analysis
Bioinformatic analysis was performed using R software (version 3.3.3) (Lucent Technologies). Principal components analysis (PCA) plot was drawn using Stats package. Dysregulated miRNAs were analyzed using limma package and showed as volcano plot with the statistical significance defined as a P value < 0.05 and the biological significance defined as a difference in fold change (FC) above 1.5 times. (Due to the limited number of miRNA profiles, we set the cutoff value of FC at 1.5 to screen out more candidate miRNAs.) Besides, dysregulated miRNAs were subjected to enrichment analysis based on annotation of (miEAA) database, which consisted of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, disease enrichment, biological process enrichment, and organ enrichment. 18 Fisher's exact test was performed to distinguish overrepresented miRNA-related items for the enrichment analysis of dysregulated miRNAs and their precursors.
| Quantitative polymerase chain reaction (qPCR) validation
So as to validate the predictive value of several potential miRNAs for clinical response to TNF inhibitor treatment, 10 candidate miR-NAs which were the top 10 dysregulated ones between responders and non-responders in microarray analysis based on the P value were chosen (miR-192-5p, miR-146a-5p, miR-19b-3p, miR-320c, miR-335-5p, miR-149-3p, miR-766-3p, let-7a-5p, miR-24-3p, and miR-1226-5p), and then, these candidate miRNAs were measured by qPCR assay for validation in total 92 RA patients. In brief, total RNA was extracted from PBMCs of each patient by TRIzol reagent (Invitrogen), and RNA concentration, purity, and integrity were evaluated and adjusted; subsequently, complementary DNA was reverse-transcribed by QuantiTect Rev. Transcription Kit (Qiagen) and then subjected to qPCR using SYBR Green Kit (TaKaRa). The PCR amplification procedures were as follows: degeneration at 95°C for 5 minutes, followed by 40 cycles at 95°C for 10 seconds, then 60 seconds at 60°C. The expressions of 10 candidate miRNAs were calculated using the 2 −ΔΔCt method with U6 as the internal reference. The primer sequences are listed in Table 1 . Note: Data were presented as mean value ± standard deviation, median (25th-75th), or count (percentage). Abbreviations: ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; LEF, leflunomide; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor.
TA B L E 1 Primer sequence list
| Statistics
Bioinformatic analysis was performed using R software (version 3.3.3) (Lucent Technologies), which was described in the above "Bioinformatic analysis" subsection. Other statistical analysis was carried out using SPSS 22.0 (IBM), and statistical graphs were drawn using GraphPad Prism software 7.01 (GraphPad Int, co, Ltd.). the data based on ITT; thus, they were not shown repeatedly in this study.
Comparison between two groups was determined by the Wilcoxon
| Characteristics of patients included in microarray
The mean age of 16 RA patients included in the microarray assay was 54.7 ± 9. Other detailed characteristics of these patients are shown in Table 2 .
| PCA plot, volcano plot, and heatmap analysis
The PCA plot showed that miRNA expression profile could mostly distinguish responders from non-responders ( Figure 1A ). However, R1 sample was close to NR3 sample and could not be clearly differentiated from NR samples, which might be because the patient with R1 sample achieved the response at just a cutoff value. The volcano plot identified 59 upregulated and 78 downregulated miRNAs in responders compared to non-responders ( Figure 1B) . Further, heatmap analysis exhibited that these dysregulated miRNAs mostly differentiated responders from non-responders ( Figure 1C ). These data implied that miRNA expression profile is implicated in the clinical response to TNF inhibitor treatment in RA patients.
| Enrichment analysis
Enrichment analysis was performed to determine the biological activities and pathways that the dysregulated miRNAs participated in. In brief, KEGG enrichment disclosed that dysregulated miRNAs were mainly implicated in the inflammation-and immune-related pathways such as inflammation-mediated chemokine and cytokine interaction, androgen receptor signaling, B-cell activation, and so on (Figure 2A) . Disease enrichment illuminated that dysregulated miRNAs were mainly enriched in neoplasms, inflammation, arthritis, and so on ( Figure 2B ). Biological process enrichment exhibited that dysregulated miRNAs mainly participated in innate immune response, inflammatory response, cell cycle cytokines, and so on ( Figure 2C) . Besides, organ enrichment showed that they were mainly implicated in fibroblasts, B lymphocytes, and so on ( Figure 2D) . These data suggested that miRNA expression profile might affect the clinical response to TNF inhibitor via affecting immune-and inflammation-related pathways and biological process.
| Selection of candidate miRNAs
In order to verify the predictive value of several potential miRNAs for clinical response to TNF inhibitor treatment, 10 candidate miR-NAs which were the top 10 dysregulated ones between responders and non-responders in microarray analysis based on the P value were chosen as follows ( 
| Characteristics of patients included in qPCR validation
The 
| Correlation of candidate miRNAs with disease activity
Positive associations of miR-146a-5p with ESR (R = 0.231, P = 0.027), miR-1226-5p with CRP (R = 0.240, P = 0.021), and let-7a-5p with DAS28
(R = 0.261, P = 0.012) were observed, while miR-335-5p was negatively correlated with DAS28 (R = −0.226, P = 0.030). No correlation of other candidate miRNAs with disease activity was found ( Table 5 ).
| Candidate miRNA expressions between responders and non-responders
Among totally 92 RA patients, 60 responders and 32 non-responders to TNF inhibitor were observed. As listed in Figure 3 , relative expression of miR-146a-5p expression (P = 0.004, Figure 3B ) in responders was higher than that in non-responders, while let-7a-5p expression (P = 0.001, Figure 3H ) was lower in responders compared with non-responders. However, relative expressions of miR-192-5p (P = 0.272, Figure 3A) , miR-19b-3p (P = 0.168, Figure 3C ), miR-320c (P = 0.114, Figure 3D ), miR-335-5p (P = 0.329, Figure 3E ), miR-149-3p (P = 0.086, Figure 3F ), miR-766-3p (P = 0.481, Figure 3G ), miR-24-3p (P = 0.223, Figure 3I ), and miR-1226-5p (P = 0.073, Figure 3J ) between responders and non-responders had no difference.
| Factors predicting clinical response
Univariate logistic analysis of factors for predicting clinical response to TNF inhibitor in all patients was assessed (Table 6) , which observed that miR-146a-5p (P = 0.006) and CRP (P = 0.003) were associated with a higher possibility to achieve clinical response, while let-7a-5p (P = 0.003) was associated with a lower possibility to achieve clinical response. All factors with a P value ≦0.1 in univariate logistic model were further analyzed by multivariate logistic regression model (Table 7) , which suggested that miR-146a-5p (P = 0.011) and CRP (P = 0.006) were independent predictive factors for better clinical response, while let-7a-5p (P = 0.002) and biologics history (P = 0.037) were independent predictive factors for worse clinical response to TNF inhibitor in RA patients.
| Predictive value of 4 independent factors for clinical response
Four independent factors in multivariate logistic analysis were further analyzed by ROC curve (Figure 4 ), which showed that 
| D ISCUSS I ON
The current study systematically explored the dysregulated miRNA miRNA is a new class of non-coding RNAs with length of approximately 23 nucleotides, which potentially construct estimated 1%-2% of the whole genome and mediate approximately 30% of all protein-encoding genes. miRNA is proposed to play critical roles in multiple physiological and pathological processes including particular contribution to inflammation formation and autoimmunity response. [19] [20] [21] Recent data suggest that circulating miR-125b expression could be served as a prognostic biomarker in RA patients treated with TNF inhibitor. 22 Another interesting study indicates that miR-146a discloses a potential predictive value for clinical response to Tripterygium wilfordii Hook F (TwHF) treatment in RA patients. 23 These previous studies suggest that miRNAs have potential value in predicting treatment efficacy in RA patients.
However, no study has explored the predictive value of comprehensive miRNA profile for the clinical response to TNF inhibitor in RA patients. Our study used the microarray to assess dysregulated miRNAs between RA responders and non-responders to TNF inhibitor, which showed that 59 upregulated and 78 downregulated miRNAs were found in responders than non-responders to TNF inhibitor by microarray, which were mainly enriched in regulating immune-and inflammation-related biological processes and to prolong the production of TNF-α, subsequently contributing to hyperimmune inflammatory responses 24 ; and (c) stimulates Th1 cells to produce IL-2, IL-12, and interferon (IFN)-γ, promoting inflammations in RA. In addition, overexpression of miR-146a-5p could target nuclear factor-kappa (NF-κB) pathway, inducing the secretion of various pro-inflammatory cytokines including TNF-α, IL-1β, and IL-17. 28 According to several reports, overexpression of miR-146a is observed in PBMCs and synovial tissue from active RA patients, which also positively correlates with ESR and DAS28. 27, 29 In our study, we discovered that miR-146a-5p was positively cor- IL-17, and NF-κB pathways. 24, 27, 28 As to predictive value of miR-146a for treatment efficacy in RA, an interesting study illuminates that miR-146a presents with an increased tendency in responders compared with non-responders to Tripterygium wilfordii Hook F (TwHF) treatment in RA patients. 23 However, no study has reported the correlation of miR-146a with clinical response to TNF inhibitor until now. Our study found that miR-146a-5p was an independent predictive factor for higher clinical response to TNF inhibitor treatment in RA patients; these might result from that: (a) miR-146a-5p high expression is associated with relatively higher disease activity, which provides a larger gap for DAS28 decrease after TNF inhibitor treatment, thereby achieving a higher possibility of clinical response; (b) miR-146a-5p may be correlated with the secretion of TNF-α, which could directly affect the efficacy of TNF inhibitor treatment; and (c) miR-146a-5p might affect TNF inhibitor sensitivity through regulating several critical genes and pathways. 6, 24, 28, 30, 31 Let-7a, one of most common subtypes of let-7 family, has been also reported to be involved in the development and progression of several diseases, such as lupus, Crohn's disease, and carcinomas, 32, 33 with the potential mechanisms as follows: (a) Let-7a represses mesenchymal stem cells (MSCs) to decrease the apoptosis of T cell, thereby promoting inflammatory responses 30 ; and (b) let-7a increases cell fraction in G2/M to decrease Cdc34 and stabilize Wee1 kinase directly, thereby stimulating fibroblast formation. 34 Partially in line with previous studies, we observed that let-7a-5p expression was positively associated with DAS28 in RA patients. The possible explanations might be that let-7a-5p promotes inflammatory responses and synovium growth in RA; thus, it correlates with higher disease activity. As to the predictive value of let-7a for clinical response in RA, no related study has been reported. Our study firstly observed that let-7a-5p was an independent factor for worse clinical response to TNF inhibitor treatment in RA patients, which might be explained by that: (a) Let-7a-5p
regulates ACPA-induced macrophage activation in RA, which leads to worse treatment outcome 35 ; (b) let-7a-5p might affect sensitivity to treatment drugs, resulting in lower clinical response. 36 In addition, we also found that CRP independently predicted higher clinical response, while biologics history independently predicted lower clinical response to TNF inhibitor in RA patients. These might result from that: (a) high CRP is correlated with high inflammation which would benefit more from anti-inflammation treatment, and it has been demonstrated in several studies that high CRP could predict clinical response to DMARDs, TNF inhibitor, and other biologics 37, 38 ; and (b) as to patients with biologics history, they are easy to produce anti-antibody when they use biologics again, which could induce secondary resistance, thereby decreasing the efficacy of treatment. 39 Most interestingly, we further discovered that the combination of miR-146a-5p, let-7a-5p, CRP, and biologics history exhibited a great predictive value for clinical response to TNF inhibitor in RA patients. This provided a novel evidence for optimizing individual treatment strategy and improving prognosis of RA. However, further prospective, multiple-center study with larger samples exploring the prognostic value of the combination of these four factors in RA patients treated with TNF inhibitor is still needed.
There were several limitations existed in this study: (a) Due to the cost of TNF inhibitor, the sample was relatively small in this study;
(b) the follow-up duration of 24 weeks was relatively short, while the long-term response was not investigated; and (c) radiographic progress was not investigated, which plays an important role in the progress of RA.
In conclusion, miRNA expression profile is closely implicated in the treatment efficacy of TNF inhibitor, and combined measurement of miR-146a-5p, let-7a-5p, CRP, and biologics history disclosed a great predictive value for clinical response to TNF inhibitor in RA patients.
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